The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China.

Ma, Yue; Zhou, Jiting; Ye, Yuxin; Wang, Xintian; Ma, Aixia; Li, Hongchao

Ma, Yue; Zhou, Jiting; Ye, Yuxin; Wang, Xintian; Ma, Aixia; Li, Hongchao.

Afiliação

Ma Y; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Zhou J; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.
Ye Y; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Wang X; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.
Ma A; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Li H; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China.

Front Oncol ; 13: 1113346, 2023.

Article em En | MEDLINE | ID: mdl-37182176

Palavras-chave

China; MSI-H/dMMR; colorectal cancer; cost-effectiveness analysis; regorafenib; serplulimab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google